After several decades of pre-clinical development, cell- and gene-based therapies for Parkinson's disease (PD) are now actively being explored. In this special supplement to the Journal of Parkinson's Disease on "Repairing the Parkinsonian Brain," experts highlight some of the current strategies being pursued to restore lost function and replace what is lost in the PD brain, with special emphasis on the challenges associated with translating advanced therapeutic approaches into pioneering clinical trials.
"Cell and gene therapy for brain diseases have been long in the making, from the first speculative ideas and the first exploratory trials in the 1980s and 1990s to the major setbacks in the cell and gene therapy fields at the turn of the century, followed by the renewed developments seen during the last decade," explained Guest Editors Anders Bjrklund, PhD, Bastiaan R. Bloem, MD, PhD, Patrik Brundin, MD, PhD, and Howard Federoff, MD, PhD.
This revival of the cell and gene therapy field has been driven by the remarkable technical developments that have given us access to increasingly more powerful molecular and genetic tools and techniques. It has opened up far more refined approaches to therapy for neurodegenerative diseases, and PD in particular. This development has gained new momentum over the last few years through the active involvement of the biotech industry, sometimes in partnership with large pharmaceutical companies."
Patrik Brundin, MD, PhD, Co-Guest Editor, Parkinson's Disease Center, Department of Neurodegenerative Science, Van Andel Institute, Grand Rapids, MI, USA
Pioneering trials in this field face regulatory and ethical challenges that are radically different from those applied to conventional drug trials. In Part I on the path to clinical trials for advanced therapies, experts review the challenges involved in the design and conduct of the early clinical trials; the different and complementary perspectives on regulatory and safety requirements; and the design and initiation of first-in-man trials. Ethical issues are explored from the investigator's, scientist's, ethicist's, and patient's perspective. including the patients concerns related to participation as a subject in demanding trials that extend over the long-term, where the outcome and risks are uncertain.
The use of advanced therapy medicinal products (ATMPs) including cell and gene treatments, are reviewed both from the investigator's perspective and the patient's perspective. Roger A. Barker, MBBS, PhD, Department of Clinical Neuroscience, University of Cambridge; and MRC-WT Cambridge Stem Cell Institute, Cambridge, UK, and coauthors point out that investigators taking an ATMP to clinical trials in patients with PD should ask themselves two key questions before embarking on such work: firstly, why are you doing it, and, secondly, do you understand what is needed to conduct a clinical trial with that product. "For ATMPs, there is an enhanced requirement for safety reporting to the regulatory authorities," noted Dr. Barker. "For example, it is imperative when conducting a trial across countries with different regulatory authorities that there is a central reporting process to capture the safety events from the trial."
For patients, a reasonable definition of an ideal advanced therapy is one that addresses one or more unmet needs of patients not covered by existing therapies, treatments with a novel mechanism of action, and most importantly, an intervention that has the potential to be disease-modifying, according to two patient advocates/scientists, Soania Mathur, MD, UnshakeableMD, Oshawa, ON, Canada, and Jon Stamford, PhD, DSc, neuroscientist and independent Parkinson's advocate. They review the issues surrounding engaging the patient community in bringing advanced therapies to the clinic, physician-patient communication, and informed consent from the patient perspective.
Participation in clinical trials and clinical use of advanced therapies have their own risk profile above and beyond standard therapeutics as evidenced by past invasive procedures. Dr. Mathur and Dr. Stamford point out that, "It is of utmost importance that clear, evidence-based information about these potential treatments is clearly communicated by those exploring their use to ensure safe and informed participation from the patient community. Patients must be able to weigh the benefits of these treatments, their limitations, and risks in order to truly give informed consent to participate in bringing these treatments to the clinic."
"The ethical and regulatory issues related to these more advanced treatment modalities are radically different from those involved in standard drug trials in that they must allow for a gradual optimization and perfection of the product, its dosing, and delivery," noted co-Guest Editor Anders Bjrklund, PhD, Wallenberg Neuroscience Center, Lund University, Sweden. "This requires that implementing novel cell- and gene-based therapies is done in a step-wise, incremental manner, which does not easily fit within the standard Phase I-III design of clinical drug trials."
The articles in Part II of this supplement highlight research promoting further development of cell and gene therapies.
Dr. Bjrklund and Malin Parmar, PhD, Department of Experimental Medical Science, Developmental and Regenerative Neurobiology, Wallenberg. Neuroscience Center, Lund University, Lund, Sweden, note that a limitation of the intrastriatal grafting approach, currently in clinical trial, is that the midbrain dopamine neurons are implanted into the target area and not in the ventral midbrain where they normally reside. This ectopic location of the cells may limit their functionality. They review impressive results with implanting the cells into the substantia nigra in rodent PD models as a way to achieve more complete circuitry repair. "This results in a remarkable degree of circuitry reconstruction that far exceeds what has been possible with ectopic intrastriatal grafts and raises the question whether intranigral transplantation should also be explored in human patients," they commented.
Many of the potentially causative and risk associated genes for PD are implicated in lysosomal function or lysosomal trafficking, indicating that lysosome dysfunction is a common denominator underlying PD disease pathology. Franz Hefti, PhD, CEO, Prevail Therapeutics (wholly-owned subsidiary of Eli Lilly and Company), New York, NY, USA, and colleagues, review the latest research on one of the lysosomal genes involved, GBA1, which encodes the lysosomal enzyme glucocerebrosidase (GCase) and has the largest impact on PD risk. Studies in mouse models indicate that a vector-based gene therapy designed to deliver a functional GBA1 gene to the brain may slow or stop disease progression.
"The next breakthrough in the treatment of PD will be based on interventions that block disease progression and restore function back to normal. In this perspective the novel treatment modalities described in this supplement hold great promise," concluded the Guest Editors.
Read this article:
- SUM Hospital conducts Odishas first stem cell transplantation - The Times of India - April 24th, 2024
- Cancer treatment: What is stem cell therapy, and how does it work? - Moneycontrol - April 24th, 2024
- The murky, unregulated world of anti-ageing stem cell therapy - The Telegraph - April 24th, 2024
- Drug Prototype Promising in Treatment of Pulmonary Disease - Medscape - April 20th, 2024
- Man Paralyzed In Surfing Accident Regains Ability to Walk After Stem Cell Treatment - The Inertia - April 20th, 2024
- Medical breakthrough: 8-year-old boy first in New York to receive FDA-approved gene therapy for rare inherited blood disorder - WABC-TV - April 20th, 2024
- Stem Cell Treatment Helped A Man Who Was Paralyzed From The Neck Down To Stand On His Own - Bored Panda - April 20th, 2024
- UM, CUHK jointly hold symposium on stem cells and regenerative medicine - gcs.gov.mo - April 20th, 2024
- Paralysed patient now able to walk as stem cell therapy shows promising results - WION - April 15th, 2024
- Andrew Steele Sees Aging as the Root of Disease - Worth - Worth Magazine - April 15th, 2024
- The astonishing effect of stem cell implants - as groundbreaking treatment 'transforms' life for those with brain damage ... - Daily Mail - April 15th, 2024
- Consumer Alert on Regenerative Medicine Products Including Stem Cells - FDA.gov - April 13th, 2024
- This Startup Wants To Be OpenAI Of Stem Cell Therapy, Targets $250B Market - Forbes - April 13th, 2024
- Brain-cell transplants are the newest experimental epilepsy treatment - MIT Technology Review - April 3rd, 2024
- Global Regenerative Medicine Market to Touch Valuation of USD 472.95 Billion by 2032, at 25.86% CAGR: Astute ... - Yahoo Finance - April 1st, 2024
- Explosive Growth Projected for Stem Cell Market, Expected to Surpass $37 Billion by 2030 As Revealed In New... - WhaTech - April 1st, 2024
- Integrating New Therapies With Autologous Stem Cell Transplant in Myeloma - Targeted Oncology - April 1st, 2024
- New tool provides researchers with improved understanding of stem cell aging in the brain - Medical Xpress - March 30th, 2024
- The ISSCR announces 2024 election results - EurekAlert - March 28th, 2024
- Exosomes and Stem Cells Are the Future of Anti-Aging - NewBeauty Magazine - March 28th, 2024
- Charles River Extends Gene Therapy Alliance with NUS Medicine - Contract Pharma - March 22nd, 2024
- Exciting opportunities in stem cell technology and regenerative biology in Indian healthcare industry - Express Healthcare - March 22nd, 2024
- Charles River Announces Extension of Gene Therapy Manufacturing Alliance with NUS Yong Loo Lin School of Medicine - Yahoo Finance - March 22nd, 2024
- Opinion: The revolutionary sickle cell therapies - MSN - March 22nd, 2024
- 10 Years of Kansas Regenerative Medicine Center - KSAL - March 22nd, 2024
- BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership - Diagnostic and Interventional Cardiology - March 17th, 2024
- Cynata Therapeutics' breakthrough in regenerative medicine - Finance News Network - March 17th, 2024
- New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia - GlobeNewswire - March 17th, 2024
- Novel 3D stem cell therapy to treat critical limb ischaemia - Drug Target Review - March 15th, 2024
- Breaking Boundaries: Pharmicell's Bold Vision for Healthcare Transformation and Monumental Growth - The Worldfolio - March 15th, 2024
- CuSTOM Organoid Research Evolving From Tool to Treatment - Research Horizons - Research Horizons - March 15th, 2024
- BioCardia and StemCardia Announce Partnership to Deliver Cell-Gene Therapy for Remuscularization of Heart - Cath Lab Digest - March 15th, 2024
- Calidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine ... - Business Wire - March 13th, 2024
- Iron restriction keeps blood stem cells young, researchers find - Phys.org - March 13th, 2024
- Vitamin A could have a key role in both stem cell biology and wound healing: Study - Medical Dialogues - March 9th, 2024
- Trends in Stem Cell Transplantation Refusal for Myeloma Treatment - Targeted Oncology - March 7th, 2024
- Stem Cell Therapy Market (CAGR) of 31.1%, Future of Market Size Emerging Technologies and their Impact on ... - Taiwan News - March 7th, 2024
- This Swedish startup wants to reduce the cost, and controversy, around stem cell production - TechCrunch - March 6th, 2024
- Advancing stem cell therapy: The regulatory process to get to clinical trials - The Economic Times - March 6th, 2024
- Transitioning from traditional surgical methods to the innovative use of stem cells - pharmaphorum - March 6th, 2024
- 'Mini organs' are grown from human stem cells taken during the late stages of pregnancy for the first time - m - Daily Mail - March 6th, 2024
- Stem cell transplant cures man of HIV and leukemia, one of five to achieve full remission - Fox 28 - March 3rd, 2024
- Stem Cell Therapy Market to Boost USD 137.5 Billion by 2034 and Projected to grow at 32.10% CAGR with increasing ... - Yahoo Finance - March 1st, 2024
- Studies expand use of stem cell therapies - WPLG Local 10 - March 1st, 2024
- Innovative therapy targets and destroys leukemia stem cells - News-Medical.Net - February 27th, 2024
- Unlocking the Potential of Stem Cells: The Medical Revolution of the Century - EIN News - February 27th, 2024
- Pelage Pharmaceuticals Announces $16.75M Series A Financing led by GV to Revolutionize Regenerative Medicine ... - Yahoo Finance - February 27th, 2024
- Say Her Name - Henrietta Lacks, The Real Mother Of Stem - Her Campus - February 27th, 2024
- California Man Free of HIV And Cancer in Astonishing Medical Recovery - ScienceAlert - February 25th, 2024
- $93 million for research into improved health for children, young people and the aged, medical devices, mental health ... - Department of Health - February 25th, 2024
- Stem Cells in Regenerative Medicine - PMC - National Center for ... - February 24th, 2024
- The Promise and Reality of Stem Cell Therapy: What You Need to Know - Corporate Wellness Magazine - February 22nd, 2024
- Stem Cell Therapy: A Beacon of Hope for Patients with Untreatable Conditions - Corporate Wellness Magazine - February 22nd, 2024
- Leading Experts in Stem Cell Therapy: A Global Overview - Corporate Wellness Magazine - February 22nd, 2024
- Can Stem Cells Help Reverse the Effects of Aging? - Corporate Wellness Magazine - February 22nd, 2024
- Stem Cell Therapy for Cancer: Hope on the Horizon? - Corporate Wellness Magazine - February 22nd, 2024
- Stem Cells and Autism: A Closer Look at Innovative Treatments - Corporate Wellness Magazine - February 22nd, 2024
- Regrowth and Restoration: The Science Behind Stem Cell Therapy for Hair - Corporate Wellness Magazine - February 22nd, 2024
- Brain Recovery: The Role of Stem Cells in Stroke and Cerebral Palsy Treatments - Corporate Wellness Magazine - February 22nd, 2024
- Turning Back the Clock: The Science of Stem Cells in Anti-Aging - Corporate Wellness Magazine - February 22nd, 2024
- Insights into cellular therapies for cancer treatment - Drug Target Review - February 22nd, 2024
- The Role of Stem Cells in Rheumatoid Arthritis Recovery - Corporate Wellness Magazine - February 22nd, 2024
- Dr Ernesto Romeros vision transforms immunotherapy regenerative medicine into a global leader in stem cell treatment - Khaleej Times - February 22nd, 2024
- World-Renowned Doctors Leading the Way in Stem Cell Research and Treatment - Medical Tourism Magazine - February 20th, 2024
- Choosing the Best: A Guide to America's Premier Stem Cell Therapy Providers - Medical Tourism Magazine - February 20th, 2024
- Navigating Through the Possibilities of Stem Cell Treatment for Eye Disorders - Medical Tourism Magazine - February 20th, 2024
- Global Leaders in Stem Cell Therapy: Where Excellence Meets Innovation - Medical Tourism Magazine - February 20th, 2024
- Excellence in Stem Cell Treatment: How the US is Pioneering Global Healthcare Solutions - Medical Tourism Magazine - February 20th, 2024
- Clarifying Memory Loss Treatments: The Role of Stem Cells - Medical Tourism Magazine - February 20th, 2024
- Battling Inflammation: Stem Cell Therapy for Rheumatoid Arthritis - Medical Tourism Magazine - February 20th, 2024
- Digestive Health and Stem Cells: Treating Ulcerative Colitis and Crohn's Disease - Medical Tourism Magazine - February 20th, 2024
- Top Stem Cell Clinics in the USA: Pioneering Treatments for Chronic Conditions - Medical Tourism Magazine - February 20th, 2024
- Stem Cells and Autism: Understanding the Potential for Innovative Treatments - Medical Tourism Magazine - February 20th, 2024
- Stopping the awakening of sleeping Acute Myeloid Leukaemia stem cells to prevent disease relapse - University of Birmingham - February 20th, 2024
- City of Hope Achieves Ground Breaking Treatment for Blood Cancer and HIV - Medriva - February 18th, 2024
- Regenerative Medicine Market Size to Worth USD 95 Billion by 2032 - InvestorsObserver - February 18th, 2024
- North America Organoids Market Projected to Reach US$ 5.35 Billion by 2030, Riding on a CAGR of 21.5% - GlobeNewswire - February 18th, 2024
- Chinese team tests lung treatment that may be first to reverse COPD damage - South China Morning Post - February 15th, 2024
- Why leukemic stem cells not harmed by chemotherapy begin to grow and produce AML cells after treatment - Medical Xpress - February 15th, 2024
- Regenerative Medicine Market is Expected to Reach $49.0 Billion | MarketsandMarkets - Yahoo Finance - February 15th, 2024
Recent Comments